A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Muzastotug (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Liver metastases; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Adagene
- 25 Jul 2024 According to an Adagene media release, data from this study were presented in a poster at SITC 2022.
- 25 Jul 2024 event According to an Adagene media release, the company is also evaluating patients treated with a 20 mg/kg loading dose followed by ADG126 10 mg/kg Q3W in combination with pembrolizumab at sites in the US and Asia Pacific. Ten patients have been enrolled in a dose expansion cohort for this dosing regimen with initial results planned for later this year.
- 25 Jul 2024 According to an Adagene media release, the company has enrolled five additional patients prospectively without peritoneal and liver metastases treated with ADG126 10 mg/kg Q3W in combination with pembrolizumab (Part 3) to further expand the patient sample with this dosing regimen.